Skip to content Skip to footer
Subscribe Now
NEWS

Merck and SciBrunch Sign ~$2.13B Exclusive Global License Agreement for SPR2015

Shots: Merck & SciBrunch have entered into an exclusive global license agreement for SPR2015, with Merck receiving exclusive rights to develop, manufacture & commercialize SPR2015 worldwide As per the deal, SciBrunch will receive ~$400M upfront & payment associated with development, commercialization & other milestones across multiple indications, representing the total deal value of ~$2.13B SPR2015…
September 28, 2026

Read more

NEWS

Envisagenics and Boehringer Ingelheim Sign >$1B Cancer Drug Development Deal

Shots: Envisagenics has entered a multi-year research collaboration & option agreement with BI to validate tumor-specific targets for developing first-in-class precision therapies for solid tumors, using Envisagenics’ AI-powered SpliceCore platform  Collaboration builds on targets identified through SpliceCore to validate their potential across ADCs, TCEs & multispecific Abs, with BI having an option to exclusively license…
September 23, 2026

Read more

MAGAZINE

PharmaShots Magazine-Aug-2026 Edition

Shots:  This edition explores Tailored Therapy, Smarter Decisions: AI in Personalized Medicine, highlighting how artificial intelligence, machine learning, multi-omics, real-world data, and predictive analytics are transforming personalized medicine into a more precise, data-driven, and patient-centric approach to care, enabling better patient stratification, treatment selection, and clinical decision-making. Through expert perspectives, feature stories, and industry insights,…
August 13, 2026

Read more

NEWS

SOPHiA GENETICS and AstraZeneca Partner to Develop Companion Diagnostics for Precision Oncology

Shots: SOPHiA GENETICS has entered a global collaboration with AstraZeneca to develop, validate, & commercialize two companion diagnostics (CDx) supporting precision oncology therapies The multi-year collaboration will leverage SOPHiA’s decentralized clinical trial assays & CDx capabilities to advance development & commercialization of the CDx programs As per the deal, SOPHiA GENETICS will develop its Solid Tumor…
August 5, 2026

Read more

Personalis
NEWS

Tempus AI to Acquire Personalis for ~$1.5B

Shots: Tempus AI has entered into a definitive agreement to acquire Personalis, expanding Tempus' capabilities in minimal residual disease (MRD) As per the deal, Personalis shareholders will receive $16.25 per share, valuing the company at an enterprise value of $1.5B, net of Tempus AI’s existing ownership interest; closing expected in late 2026 or early 2027…
July 21, 2026

Read more

VIEWPOINTS

Michael Wysocki on Precision Molecular Imaging & PSMA PET Innovation: Blue Earth Diagnostics’ Vision for Personalized Prostate Cancer Care

Shots:  Blue Earth Diagnostics is advancing precision molecular imaging in prostate cancer through its F-18 PET imaging portfolio, with POSLUMA and Axumin designed to improve disease localization, support earlier clinical decision-making, and enhance physician confidence, particularly in patients experiencing biochemical recurrence.  At SNMMI 2026, the company presented new evidence highlighting POSLUMA's strong detection performance at low PSA levels, reduced urinary…
July 13, 2026

Read more

NEWS

Sanyou Biopharmaceutical and Baiyunshan Xihe Partner on AI-Driven Radiopharmaceutical Development

Shots: Sanyou & Baiyunshan Xihe have entered into a strategic collaboration to co-develop novel radiopharmaceuticals & radiodiagnostic products by combining AI-driven drug discovery with nuclear medicine expertise As per the deal, Sanyou Bio will contribute its AI-STAL libraries & AI-Drug Accelerator platform for target molecule discovery, while Baiyunshan Xihe will lead radionuclide production, radiolabeling, preclinical…
July 6, 2026

Read more

NEWS

Guardant Health and Nuvalent Partner on Precision Oncology Diagnostics

Shots: Guardant Health has entered into a multi-year strategic collaboration with Nuvalent to support the development & potential commercialization of Nuvalent’s oncology pipeline using the Guardant Infinity platform The partnership will use Guardant’s tissue & liquid biopsy tests to support Nuvalent’s global clinical studies & evaluate companion diagnostic development for Nuvalent’s investigational cancer therapies The…
May 1, 2026

Read more

VIEWPOINTS

Turning Genome Data into Clinical Insight: Jehee Suh of Inocras on AI-Driven Genomics 

Shots:  Inocras is advancing the clinical adoption of whole-genome sequencing (WGS) by transforming it from a research tool into a standardized diagnostic workflow, refining its algorithms through thousands of real-world patient cases to deliver actionable genomic insights in routine care.  Through platforms such as CancerVision, RareVision, and MRDVision, the company integrates deep genomic analytics, AI-driven bioinformatics, and clinical services like genetic counseling and…
March 31, 2026

Read more

THOUGHTSPOT

Whole-genome sequencing meets real-world outcomes: what 1,364 breast cancer genomes reveal about treatment response

Author: Jehee Suh, CEO, Inocras Breast cancer is not one disease. It’s a set of biologically distinct malignancies that differ by subtype, clinical behavior, and most importantly, how patients respond to therapy. Over the past two decades, oncology has made real progress by aligning treatment to a handful of established biomarkers (ER/PR, HER2, BRCA1/2). Despite…
March 3, 2026

Read more

Load more